Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Tamoxifen Citrate or Letrozole with or without Palbociclib in Treating Patients with Stage I-III Invasive Breast Cancer before Surgery

This phase II clinical trial studies how well tamoxifen citrate or letrozole with or without palbociclib work in treating patients with stage I-III invasive breast cancer before surgery. Antihormone therapies, such as tamoxifen citrate and letrozole, may lessen the amount of estrogen made by the body. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving tamoxifen citrate or letrozole with or without palbociclib may work better in treating patients with stage I-III invasive breast cancer.
Breast
Phase II
Adults
Chemotherapy - cytotoxic, Hormonal Therapy, Mol. targeted/Immunotherapy/Biologics
Letrozole (Femara), Palbociclib, Tamoxifen
Mayer, Ingrid
Local
Vanderbilt University
04-04-2018
Treatment
VICCBRE1732
NCT02764541

Eligibility

18 Years
FEMALE
NO
Inclusion Criteria:

Patients must have stage I to III histologically confirmed invasive carcinoma of the breast; a minimum tumor size of at least 1.5 cm determined by physical exam or imaging (whichever is larger) is required

Patients must have histologically confirmed hormone receptor positive (ER and/or progesterone receptor [PR]), human epidermal growth factor receptor 2 (HER2) negative, early invasive breast cancer; ER, PR and HER2 measurements should be performed according to institutional guidelines, in a Clinical Laboratory Improvement Amendments (CLIA)-approved setting in the United States (US) or certified laboratories for non-US regions; cut-off values for positive/negative staining should be in accordance with current ASCO/CAP (American Society of Clinical Oncology/College of American Pathologists) guidelines; central confirmation is not required for ER, PR, or HER statuses

Patients with equivocal HER2 in situ hybridization results according to current ASCO/CAP guidelines are allowed, as long as the clinician has determined that they should be treated as HER2 negative

For the window phase: Patients must have histologically confirmed invasive lobular carcinoma or invasive ductal carcinoma; no central confirmation of histological subtype is necessary for enrollment; patients with mixed invasive ductal and lobular carcinoma are eligible and will be stratified as ductal

For the treatment phase: Patients with any histological subtype are eligible

Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Absolute neutrophil count >= 1,500/mm^3

Platelets >= 100,000/mm^3

Hemoglobin >= 10 g/dL

Total serum bilirubin =
Aspartate amino transferase (AST or serum glutamic oxaloacetic transaminase [SGOT]) and alanine amino transferase (ALT or serum glutamate pyruvate transaminase [SGPT]) =
Serum creatinine below institutional upper limit of normal or creatinine clearance >= 60 mL/min/1.73 m^2 for patients with serum creatinine levels above institutional ULN

Postmenopausal is defined either by age >= 60, prior bilateral oophorectomy, or age
Patient must agree to the required research biopsies at baseline and after the two-week treatment with endocrine therapy in the initial part of the study (“window phase”); or at baseline and after two-week treated with endocrine therapy plus or minus palbociclib for those patients enrolled directly into the treatment phase of the study

Patients must be able and willing to swallow and retain oral medication without a condition that would interfere with enteric absorption

Breast imaging should include imaging of the ipsilateral axilla; for subjects with a clinically negative axilla, a sentinel lymph node biopsy will be performed either before or after preoperative therapy at the discretion of the subject’s physicians; for subjects with a clinically positive axilla, a needle aspiration, core biopsy or sentinel lymph node (SLN) procedure will be performed to determine the presence of metastatic disease in the lymph nodes

Patients with multifocal or multi-centric disease are eligible if the treating clinician has determined the patient should be treated as ER+ and HER2- negative

Bilateral breast cancers are allowed if the treating clinician has determined the patient should be treated as ER+ and HER2- negative

Serum or urine pregnancy test must be negative in women judged premenopausal within 7 days of randomization, or in women with amenorrhea of less than 12 months at time of randomization; pregnancy testing does not need to be pursued in patients who are judged as postmenopausal before randomization, as determined by local practice, or who have undergone bilateral oophorectomy, total hysterectomy, or bilateral tubal ligation

Premenopausal patients must agree to use adequate contraception for the duration of protocol treatment and for 6 months after the last treatment with palbociclib; adequate contraception is defined as one highly effective form (i.e. abstinence, male or female sterilization) OR two effective forms (e.g. non-hormonal intrauterine device [IUD] and condom/occlusive cap with spermicidal foam/gel/film/cream/suppository); hormonal contraceptive methods are not allowed; patients with hormonal IUD in place are eligible provided the hormonal IUD is removed or replaced by a non-hormonal IUD prior to treatment initiation

Patients with a history of ipsilateral or contralateral ductal carcinoma in situ (DCIS) are eligible

Patients may concurrently receive bisphosphonates or rank ligand inhibitors while on this study if necessary for treatment or prevention of osteopenia or osteoporosis; prior treatment with LHRH agonists is allowed for premenopausal women; topical vaginal estrogen therapy is allowable

Ability to understand and the willingness to sign a written informed consent document



Exclusion Criteria:

Concurrent therapy with other investigational products

Prior therapy with any cyclin-dependent kinase (CDK) inhibitor

Patients with stage IV breast cancer are not eligible; baseline staging to document absence of metastatic disease is not required, however is recommended as determined by institutional practice (in patients where there may be a reasonable suspicion of advanced disease e.g., large tumors, clinically positive axillary lymph nodes, signs and symptoms); if performed, reports of these examinations must be available; examination type for staging, i.e. X-ray, sonography, bone scans, computed tomography (CT), magnetic resonance imaging (MRI), and/or positron emission tomography (PET)-CT, is at the discretion of the investigator

History of allergic reactions attributed to compounds of chemical or biologic composition similar to palbociclib

Patients receiving any medications or substances that are potent inhibitors or inducers of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP3A4) isoenzymes within 7 days of randomization for list of CYP3A inhibitors and inducers

Uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes, or psychiatric illness/social situations that would limit compliance with study requirements; ability to comply with study requirements is to be assessed by each investigator at the time of screening for study participation

Pregnant women, or women of childbearing potential without a negative pregnancy test (serum or urine) within 7 days prior to randomization, irrespective of the method of contraception used, are excluded from this study; breastfeeding must be discontinued prior to study entry

Patients with a history of malignancy are ineligible except for the following circumstances: * Patients with a history of invasive breast cancer are eligible if they have been disease-free for a minimum of five years * Patients with a malignancy history other than invasive breast cancer are eligible if they have no active malignancy and are deemed by the investigator to be at low risk for recurrence of that malignancy * Patients with the following cancers are eligible: ductal carcinoma in situ of the breast, cervical cancer in situ, and non-metastatic non-melanomatous skin cancers

Patients on combination antiretroviral therapy, i.e. those who are human immunodeficiency virus (HIV)-positive, are ineligible; HIV testing is not required, but patients must not be known to be HIV-positive

Patients receiving concurrent exogenous hormone therapy (hormone replacement therapy, oral or any other hormonal contraceptives such as hormonal contraceptive coil are not eligible

Patients are not eligible if they have previously received endocrine therapy within 5 years prior to diagnosis of the current malignancy; this includes use for prophylactic reasons, including treatment of osteoporosis or cancer prevention with tamoxifen, raloxifene, or aromatase inhibitors (AI)

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: